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(57) ABSTRACT 
The present invention discloses methods of reducing injury 
resulting from cardiovascular disease, such as myocardial 
infarction, and/or promoting myocardial repair. The methods 
include administering an ephrin and pharmaceutical compo 
sitions including ephrins to a Subject. Kits useful for accom 
plishing the same are also provided. 
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METHODS OF REDUCING MYOCARDAL 
INURY FOLLOWING MYOCARDIAL 
INEARCTION 
CROSS-REFERENCE TO RELATED 
APPLICATION 
0001. This application is a divisional of U.S. patent appli 
cation Ser. No. 13/299,096, filed Nov. 17, 2011, now allowed, 
and claims the benefit of U.S. Provisional Application No. 
61/414,741, filed Nov. 17, 2010. The disclosure of each appli 
cation is incorporated by reference herein in its entirety. 
STATEMENT REGARDING ELECTRONIC 
FILING OF A SEQUENCE LISTING 
0002 A Sequence Listing in ASCII text format, submitted 
under 37 C.F.R.S 1.821, entitled 5218-198TSDV ST25.txt, 
6,874 bytes in size, generated on Nov. 6, 2013 and filed via 
EFS-Web, is provided in lieu of a paper copy. This Sequence 
Listing is hereby incorporated by reference into the specifi 
cation for its disclosures. 
FIELD OF THE INVENTION 
0003. The present invention concerns methods of reduc 
ing injury resulting from cardiovascular disease or events, 
Such as myocardial infarction, and/or promoting myocardial 
repair. The present invention further concerns pharmaceutical 
compositions and kits useful for accomplishing the same. 
BACKGROUND OF THE INVENTION 
0004 The heart generally lacks an endogenous regenera 
tive capacity Sufficient for repair after injury. Consequential 
left ventricular (LV) remodeling after myocardial infarction 
(MI) leads to LV dilatation, ultimately leading to heart failure 
(Pfeffer & Braunwald, 1991; Gaudronet al., 1993; Goldstein 
et al., 1998: Holmes et al., 2005). To reduce this epidemio 
logic and fiscal burden, it is imperative that strategies be 
developed to preserve cardiomyocyte Survival, Subsequently 
reducing myocardial infarct size, and reducing overall LV 
remodeling. 
0005 Immediately after coronary occlusion, ischemic 
myocytes downstream from the occlusion become necrotic 
and/or undergo apoptosis (Cheng et al., 1996; MacLellan & 
Schneider, 1997; Freude et al., 1998) or autophagy (Nakai et 
al., 2007: Dorn & Diwan, 2008; Porrello & Delbridge, 2009). 
Cardiac troponin I is released, which can be measured in 
plasma and correlates to the size of injury (Bodor et al., 1995; 
Chapelle, 1999: Braunwald et al., 2002: Nageh et al., 2003: 
Oyama & Sisson, 2004; Jaffe, 2005). Neutrophils infiltrate 
the tissue immediately, while leukocytes, predominantly 
macrophages, arrive shortly thereafter and participate in 
digestion of necrotic cellular debris. Neutrophils in the 
ischemic tissue can be toxic to the Surrounding myocytes, 
because they release reactive oxygen species and proteolytic 
enzymes which further injure the Surrounding myocytes 
(Lefer & Granger, 2000; Frangogiannis et al., 2002; Frango 
giannis, 2008: Lambert et al., 2008; Nah& Rhee, 2009). Once 
damage occurs, a hypocellular scar forms that leads to con 
tractile dysfunction and heart failure (Fishbein et al., 1978; 
Frangogiannis et al., 2002; Virag & Murry, 2003; Dorn, 
2009). 
0006 Since the discovery of the Eph (erythropoietin-pro 
ducing hepatocellular carcinoma) receptor tyrosine kinase 
(RTKs) in 1987 (Hirai et al., 1987), a great deal of effort has 
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been focused on elucidating Eph receptor tyrosine kinase 
(RTK) and ephrin ligand signaling in the context of numerous 
pathologies. A distinguishing characteristic of Eph-ephrin 
interactions is the ability to generate bidirectional signaling. 
“Forward” signaling occurs in the direction of the receptor 
expressing cell, while “reverse' signaling occurs in the direc 
tion of the ligand expressing cell (Bruckner et al., 1997: 
Mellitzer et al., 1999; Klein, 2001: Kullander & Klein, 2002). 
Upon ligand binding and receptor activation, endocytic inter 
nalization of the complex occurs (Pasquale, 2010), leading to 
downregulation of the protein. Intracellular cascades down 
stream of Eph/ephrin signaling are involved in cellular Sur 
vival, growth, differentiation, and motility (Zhou, 1998; Kul 
lander & Klein, 2002; Arvanitis & Davy, 2008: Pasquale, 
2008, 2010). The EphA1 receptor has been linked to angio 
genesis through endothelial cell migration. Like the ephrinA1 
ligand, EphA1 is induced by TNF-C. VEGF, and IL-B, lead 
ing to cellular adhesion via integrins and vessel destabiliza 
tion (Pandey et al., 1995: Cheng et al., 2002a: Cheng et al., 
2002b: Moon et al., 2007). Similarly, the EphA2 receptor, 
expressed on endothelial cells, is widely reported as a key 
player in angiogenesis, particularly in development and can 
cer (Ogawa et al., 2000; Brantley-Sieders et al., 2004; Brant 
ley-Sieders et al., 2006; Wykosky et al., 2008). 
0007 Of the at least five ephrinA ligands, ephrinA1 is 
unique in that it is currently the only ligand that binds all eight 
EphA receptors known to be expressed in mice. Aside from its 
predominant characterization as a pro-angiogenic factor in 
adult mouse tumors, (Easty et al., 1999; Ogawa et al., 2000; 
Iida et al., 2005), ephrin A1 appears to be involved in inflam 
mation and apoptosis. It was reported in 2006 that Eph recep 
tors are differentially expressed at early and late stages of 
inflammation (Ivanov & Romanovsky, 2006). For example, at 
earlier stages of inflammation, EphA2 and EphrinB2 expres 
sion is predominantly localized to epithelial and endothelial 
cells, promoting disruption of the endothelial/epithelial bar 
rier. However, as the inflammatory process progresses, 
expression of EphA1, EphA3, EphB3, and EphB4 on these 
cells decreases, allowing infiltrating leukocytes to adhere to 
endothelial cells by disrupting endothelial/epithelial barriers 
(Ivanov & Romanovsky, 2006). EphrinA1/EphA receptor 
expression changes also appear to be involved in regulating 
pathways involved with apoptosis. In 2006, Munoz and col 
leagues reported that Eph A4 deficient mice exhibited both 
defective T cell development and increased numbers of apo 
ptotic cells (Munoz et al., 2006). 
SUMMARY OF THE INVENTION 
0008 Embodiments of the present invention provide 
methods of reducing injury following cardiovascular events 
or disease in a subject in need thereof, comprising adminis 
tering to the Subject a therapeutically effective amount of an 
ephrin. Further embodiments of the present invention provide 
administering the ephrin at the time of onset of the cardiovas 
cular event or disease, after awareness of the cardiovascular 
event or disease and/or before the onset of the cardiovascular 
event or disease. 
0009 Embodiments of the present invention provide 
methods of reducing injury following myocardial infarction 
in a subject in need thereof, comprising administering to the 
subject a therapeutically effective amount of an ephrin. Fur 
ther embodiments of the present invention provide adminis 
tering the ephrin at the time of myocardial infarction, after 
myocardial infarction and/or before myocardial infarction. 
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00.10 Embodiments of the present invention also provide 
methods of promoting myocardial repair following myocar 
dial injury in a Subject in need thereof, comprising adminis 
tering to the Subject a therapeutically effective amount of an 
ephrin. According to particular embodiments, the ephrin can 
be administered at the time of myocardial infarction, after 
myocardial infarction and/or before myocardial infarction. 
0011 Embodiments of the present invention further pro 
vide methods of reducing myocardial injury and/or promot 
ing mycocardial repair in reperfused or nonreperfused myo 
cardial tissue. 
0012. Further embodiments of the present invention pro 
vide a pharmaceutical composition comprising an ephrin and 
a pharmaceutically acceptable carrier. In some embodiments, 
the pharmaceutical composition further comprises an agent 
useful for treating cardiovascular events or disease. In some 
embodiments, the agent is useful for treating myocardial inf 
arction. 
0013. A still further embodiment of the present invention 
provides a kit comprising a composition comprising an eph 
rin in a pharmaceutically acceptable carrier and a container 
suitable for delivery of the composition into a parental deliv 
ery system. In some embodiments, the parenteral delivery 
system is an intramyocardial administration device. 
0014. The foregoing and other embodiments of the present 
invention are explained in greater detail throughout. 
BRIEF DESCRIPTION OF THE DRAWINGS 
0015 FIG. 1. EphrinA1-Fc distribution in the infarcted 
myocardium. Anti-human IgG-Fc staining to detect exog 
enous ephrinA1-Fc in the myocardium 30 min after injection. 
This representative image shows an abundant concentration 
of ephrin Al-Fc on the epicardial Surface, as well as transmu 
ral expression of the protein. To a lesser extent, ephrin A1-Fe 
was also detected 4 hours post-injection, but could not be 
detected 24 hours or 4 days post-injection. Scale bar, 200 um. 
0016 FIG. 2. Ephrin Al-Fc administration reduces infarct 
size, chamber dilation, necrosis, and thinning of the left ven 
tricular free wall. Representative histological images shown 
are of vehicle-treated (A) and ephrinA1-Fc-treated (B) hearts 
four days post-MI. There was a 50% reduction in infarct size 
(C), 64% less necrosis (D), 35% less chamber dilation (E), 
and 32% less thinning of the left ventricular free wall (F). n=7 
control, n=9 IgG-Fc, n=9 ephrinA1-Fc, P<0.05: it different 
from control, * different from IgG-Fc. LV: Left Ventricle: RV: 
Right Ventricle: N: Necrosis; G: Granulation tissue. 
0017 FIG. 3. Intramyocardial ephrinA1-Fc administra 
tion reduces tissue injury. Administration of ephrin Al-Fc 
resulted in a 54% reduction in cTnI serum levels 4 days after 
MI (A), (n=8 control, n=13 vehicle, n=11 ephrin Al-Fc). 
Cleaved PARP expression was reduced with ephrin Al-Fc 
administration (B). BAG-1 protein (C) increased with eph 
rin Al-Fc administration by 36% when normalized to 
GAPDH. P-0.05: it different from control, * different from 
MI. 
0018 FIG. 4. Ephrin Al-Fc reduces inflammatory cell 
infiltration. EphrinA1-Fc administration significantly 
reduced infiltration of neutrophils (A) and leukocytes (B) at 4 
days. n=3 control, n=9 IgG-Fc, n=9 ephrinA1-Fc. P<0.05: it 
different from control, * different from MI. Representative 
images of Ly6G + neutrophil infiltration (top panels) and 
CD45+ pan-leukocyte infiltration (bottom panels) are shown 
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in control (left), vehicle-treated (middle) and ephrinA1-Fc 
treated (right) hearts. Scale bar in A (Control) represents 50 
lm. 
0019 FIG. 5. Altered gene expression of ephrin A1 and 
EphA receptors in response to MI and MI-- ephrin Al-Fc. 
Following MI, ephrinA1 gene expression was significantly 
reduced (grey bars), and remained relatively unchanged in 
response to ephrin Al-Fc administration (black bars). Recep 
tors A1, A2, A3 and A7 were significantly upregulated in 
response to MI, by 5-fold, 2-fold, 5-fold and 28%, respec 
tively, while EphA4 remained unchanged. Eph A6 was 
detected in control hearts but dropped significantly following 
MI, and expression was not recovered with ephrin Al-Fc 
administration. In response to ephrin Al-Fc administration, 
receptors A1 and A2 were further upregulated, by approxi 
mately 2-fold each, and A4 was also upregulated by almost 
2-fold. Values were calculated using the Ct method, normal 
ized to GAPDH, and presented here as fold changes relative 
to uninjured control (white bars), n=8 control, n=8 MI, n=8 
ephrinA1-Fc. P<0.05: t different from control, * different 
from MI. 
0020 FIG. 6. Ephrin A1 protein distribution in the myo 
cardium. Representative immunostaining for ephrin A1 pro 
tein showed a low basal expression of ephrin A1 in cardi 
omyocytes of control hearts (A and D), intense staining in 
endo- and epicardial myocytes following 4 days non reper 
fused MI (Band E), and more intense staining in myocytes as 
well as numerous granulation tissue cells in the infarct Zone 
following ephrin Al-Fc treatment at 4 days post-MI (C and F). 
Ephrin A1 total protein expression (G) was reduced by 50% in 
response to MI, but only reduced 36% in response to eph 
rin Al-Fc administration (normalized to GAPDH). Scale 
bars: 100 um in A, 20 Lum in D. 
(0021 FIG. 7. EphrinA1-Fc increases pAKT/AKT. (A), 
representative blot of phosphorylated and total AKT, with the 
average densitometric analysis of three repeated blots. n=3 
control, n=3 MI, n=3 ephrinA1-Fc. P-0.05: it different from 
control, *different from MI. (B), representative blot of NF-kB 
p65 protein expression, normalized to GAPDH. n=3 control, 
n=3 MI, n=3 ephrinA1-Fc. 
DETAILED DESCRIPTION 
0022. The foregoing and other aspects of the present 
invention will now be described in more detail with respect to 
other embodiments described herein. It should be appreciated 
that the invention can be embodied in different forms and 
should not be construed as limited to the embodiments set 
forth herein. Rather, these embodiments are provided so that 
this disclosure will be thorough and complete, and will fully 
convey the scope of the invention to those skilled in the art. 
0023. Unless otherwise defined, all technical and scien 
tific terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which this 
invention pertains. The terminology used in the description of 
the invention herein is for the purpose of describing particular 
embodiments only and is not intended to be limiting of the 
invention. As used in the description of the invention and the 
claims set forth herein, the singular forms “a,” “an and “the 
are intended to include the plural forms as well, unless the 
context clearly indicates otherwise. 
0024 All publications, patent applications, patents and 
other references cited herein are incorporated by reference in 
their entireties for the teachings relevant to the sentence and/ 
or paragraph in which the reference is presented. 
0025. As used herein, the phrase “reducing injury” refers 
to any type of action or treatment that imparts an effect to 
decrease, minimize or even maintain the level of injury. 
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Accordingly, reducing injury indicates that the Subject's con 
dition is not worsened and may be improved with respect to 
the injury of concern as compared with the level of injury in 
the absence of treatment or action described herein to reduce 
injury. 
0026. As used herein, “cardiovascular disease' or “heart 
disease' is a term used to describe a range of diseases or 
events that affect the heart and/or vasculature. Types of heart 
disease include, but are not limited to, coronary heart disease, 
cardiomyopathy, ischemic heart disease, heart failure, 
inflammatory heart disease, valvular heart disease and aneu 
rysm. Heart disease can be assessed using clinical parameters 
and/or assessments known to those skilled in the art of diag 
nosing and/or treating the same, for example, physical exami 
nations, detection of signs and symptoms of cardiovascular 
disease, electrocardiogram, echocardiogram, chest X-ray, 
blood tests to detect cardiac biomarkers, etc. Biomarkers 
typically used in the clinical setting include, but are not lim 
ited to, cardiac troponins (C. T. and I), CK and CK-MB, and 
myoglobin. 
0027. As used herein, “myocardial infarction” or “MI” 
refers to a rapid development of myocardial necrosis, which 
may be caused by the interruption of blood supply to the heart 
resulting in a critical imbalance between oxygen Supply and 
demand of the myocardium. This may result from plaque 
rupture with thrombus formation in a coronary vessel leading 
to an acute reduction of blood Supply to a portion of the 
myocardium; that is, an occlusion or blockage of a coronary 
artery following the rupture of a susceptible atherosclerotic 
plaque. Ifuntreated for a sufficient period of time, the result 
ing ischemia or restriction in blood Supply and oxygen short 
age can cause damage or death, i.e., infarction of the heart. In 
general, this damage is largely irreversible, and clinical thera 
pies thus far mainly aim at delaying the progression of heart 
failure to prolong survival. Myocardial infarction can be 
assessed using clinical parameters and/or assessments known 
to those skilled in the art of diagnosing and/or treating the 
same, for example, physical examinations, detection of signs 
and symptoms of myocardial infarction, electrocardiogram, 
echocardiogram, chest X-ray, blood tests to detect cardiac 
biomarkers including troponins, CK, and CK-MB, etc. 
0028. As used herein, “reperfusion” refers to the restora 
tion of blood flow or supply to the myocardium or myocardial 
tissue that has become ischemic or hypoxic. Modalities for 
reperfusion include, but are not limited to, chemical dissolu 
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tration of vasodilators, angioplasty, percutaneous coronary 
intervention (PCI), catheterization and coronary artery 
bypass graft (CABG) Surgery. 
0029. As used herein, "ephrin' or “ephrins (erythropoi 
etin-producing hepatocellular (Eph)/Eph receptor interacting 
protein refers to a family of membrane-attached proteins that 
are ligands of class V (EPH-related) receptor protein-tyrosine 
kinases. Ephrins are divided into the ephrin-A (EFNA) class, 
which are anchored to the membrane by a glycosylphosphati 
dylinositol linkage, and the ephrin-B (EFNB) class, which are 
transmembrane proteins. Ephrin-A (EFNA) class includes 
ephrin A1, ephrin A2, ephrin A3, ephrin A4 and ephrin A5, as 
well as variants and isoforms thereof. Ephrin-B (EFNB) class 
includes ephrin B1, ephrin B2 and ephrin B3, as well as 
variants and isoforms thereof. 
0030. According to embodiments of the present invention, 
ephrins employed in the methods described herein include the 
full length polypeptide, polypeptide fragments of the full 
length polypeptide, variants and isoforms of the ephrin, 
fusion proteins and/or chimeric proteins comprising, consist 
ing essentially of and/or consisting of an ephrin or a polypep 
tide fragmentofanephrinjoined to an exogenous polypeptide 
sequence, and immunogenic fragments of the ephrin. Non 
limiting examples of polypeptide sequences of ephrin A1, and 
isoforms thereof, include human (Accession Nos. P20827.2, 
AAH32698.1, NP 004419.2 and NP 872626.1), mouse 
(Accession Nos. P52793.1, NP 034237.3 
NP 001155897.1), wild boar (Accession 
NP 001116582.1), cattle (Accession No. NP 001029464. 
1), Zebrafish (Accession No. NP 95077.2), dog (XP 
547553.1 and XP 852071.1), xenopus laevis (Accession 
Nos. NP 001088798.1 and NP 001081390.1), rat (Acces 
sion No. NP 446051.2), chimpanzee (Accession Nos. 
XP 001141980.2 and XP 003308473.1) and Xenopus 
tropicalis (Accession No. NP 00101 1206.1) sequences, as 
well as sequences of synthetic constructs (Accession Nos. 
ABM81648.1, AAX42510.1 and AAX2994.9.1). 
0031. The ephrin may be mammalian, non-mammalian, 
recombinant, purified, non-purified or a crude extract com 
prising an ephrin. In some embodiments, the ephrin belongs 
to the ephrin-A class of ephrins. In further embodiments, the 
ephrin is ephrin A1, ephrin A2, ephrin A3, ephrin A4, ephrin 
A5, or a combination thereof. In still other embodiments, the 
ephrin is ephrin A1. 
0032. In some embodiments, the polypeptide sequence for 
isoform 1 of ephrin A1 from mouse is: 
(SEQ ID NO: 1) 
lic cslaaadir hivfwns Snp kfreedytvh volndylidii cphyeddisva 
mvehqey vac opqskdovrw incinrpsakhg peklsekfor ftp filgkef 
kpiyhdes go lklkvt Vngk ithnpdahvin poekirlqadd pevovlhsig 
v Wavlillpll illqsq. 
0033. In another embodiment, the polypeptide sequence 
for isoform 2 of ephrin A1 from mouse is: 
(SEQ ID NO: 2) 
hdey vacqpq skdqvir Wincn rpsakhgpek lisekiforftp filgkefkeg 
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0034. In another embodiment, the polypeptide sequence 
for isoform 1 of ephrin A1 from human is: 
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93%, 94%. 95%,96%.97%, 98%, 99% and/or 100% identity 
with another amino acid sequence. 
(SEQ ID NO : 3) 
1 meflwapllig lcc slaaadr htvfwns Snp kfrnedytih volndyvdii cphyedhsva 
61 daamedyily liveheeydlic qpqskdovrw qcnirpsakhg peklsekfor ftpftligkef 
121keghsyyyis kpihdhedrc lirlkvtv.sgk ith sporandn pgekirlaadd pewrvlhsig 
181hsaaprlfpl. awtvilllpll llotp. 
0035. In another embodiment, the polypeptide sequence 
for isoform 2 of ephrin A1 from human is: 
0039. In further embodiments, the present invention may 
comprise, consist essentially of and/or consist of nucleic 
(SEQ ID NO : 4) 
1 meflwapllig lcc slaaadr htvfwns Snp kfrnedytih volndy voii cphyedhsva 
61 daamedyily liveheeydlic qpqskdovrw qcnirpsakhg peklsek for ftpftlgkef 
121keghsyyyis hispcandinpg ekirlaaddpe virvlh sighs aaprlfplaw tvlllpllll 
181 qtp . 
0036. In further embodiments, the ephrin may comprise, 
consist essentially of, and/or consist a fragment of the full 
length polypeptide as set forth in any of SEQID NOS:1-4. In 
an embodiment, this fragment may comprise, consist essen 
tially of, and/or consist of the extracellular domain of the 
ephrin. In a particular embodiment, the fragment may be 
amino acids 1-182 of SEQ ID NO:1. In another particular 
embodiment, the fragment may beamino acids 1-182 of SEQ 
ID NO:3. In yet another particular embodiment, the fragment 
may be amino acids 22-131 of SEQID NO:3. 
0037. In particular embodiments, the ephrin comprises, 
consists essentially of and/or consists of a fusion and/or chi 
meric protein that comprises, consists essentially of and/or 
consists of a polypeptide fragment of an ephrin fused to an 
exogenous peptide sequence. In particular embodiments, the 
exogenous peptide sequence of the fusion and/or chimeric 
protein is the Fc region of human IgG (where there are at least 
four IgG subtypes—IgG, IgG, IgG and IgG), in particular 
IgG. In further embodiments, the ephrin is mouse ephrin 
Al-Fc. Mouse ephrin Al-FC is a chimeric protein that com 
prises the extracellular domain of mouse ephrin-A1 fused by 
means of a polypeptide linker to the Fc region of human IgG. 
In still further embodiments, the ephrin is human ephrin 
Al-Fc. Human ephrin Al-FC is a chimeric protein that com 
prises the extracellular domain of human ephrin A1 fused to 
the Fc region of human IgG. In still further embodiments, the 
ephrin may be a disulfide-linked homodimer. 
0038. The present invention further includes the use of 
homologs, as well as methods of obtaining homologs, of the 
polypeptides and/or fragments employed in this invention. As 
used herein, an amino acid sequence or protein is defined as a 
homolog of a polypeptide or fragment of the present inven 
tion if it shares significant homology or identity to one of the 
polypeptides and/or fragments of the present invention. Sig 
nificant homology means at least 60%. 65%, 75%, 80%, 81%, 
82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 
92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% and/or 100% 
homology with another amino acid sequence. Significant 
identity means at least 60%. 65%, 75%, 80%, 81%, 82%, 
83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 
acids that encode the polypeptides and/or fragments that 
comprise the ephrins as set forth herein. These nucleic acids 
can be part of a recombinant nucleic acid construct compris 
ing any combination of restriction sites and/or functional 
elements as are well known in the art that facilitate molecular 
cloning and other recombinant DNA manipulations. Thus, 
the present invention further provides a recombinant nucleic 
acid construct that comprises a nucleic acid encoding a 
polypeptide and/or biologically active fragment employed in 
this invention. 
0040. The present invention further includes a vector com 
prising a nucleic acid encoding a polypeptide and/or fragment 
employed in this invention. The vector can be an expression 
vector which contains all of the genetic components required 
for expression of the nucleic acid in cells into which the vector 
has been introduced, as are well known in the art. The expres 
sion vector can be a commercial expression vector or it can be 
constructed in the laboratory according to standard molecular 
biology protocols. 
0041 As used herein, the term “protein’ or “polypeptide' 
is used to describe a chain of amino acids that correspond to 
those encoded by a nucleic acid. A polypeptide or protein of 
this invention can be a peptide, which usually describes a 
chain of amino acids of from two to about 30 amino acids. The 
term polypeptide as used herein also describes a chain of 
amino acids having more than 30 amino acids and can be a 
fragment or domain of a protein or a full length protein. 
Furthermore, as used herein, the term polypeptide can refer to 
a linear chain of amino acids or it can refer to a chain of amino 
acids that has been processed and folded into a functional 
protein. It is understood, however, that 30 is an arbitrary 
number with regard to distinguishing peptides and polypep 
tides and the terms can be used interchangeably for a chain of 
amino acids. The polypeptides of the present invention can be 
obtained by isolation and purification of the polypeptides 
from cells where they are produced naturally, by enzymatic 
(e.g., proteolytic) cleavage, and/or recombinantly by expres 
sion of nucleic acid encoding the polypeptides or fragments 
of this invention. The polypeptides and/or fragments 
US 2014/0056925 A1 
employed in this invention can also be obtained by chemical 
synthesis or other known protocols for producing polypep 
tides and fragments. 
0042. The term “fragment, as applied to a polypeptide, 
will be understood to mean an amino acid sequence of 
reduced length relative to a reference or full length polypep 
tide or amino acid sequence and comprising, consisting 
essentially of and/or consisting of an amino acid sequence of 
contiguous amino acids identical or almost identical (e.g., 
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% 
and/or 100% identical) to the reference or full length 
polypeptide oramino acid sequence. Such a polypeptide frag 
ment according to the invention may be, where appropriate, 
included in a larger polypeptide of which it is a constituent. In 
Some embodiments, such fragments can comprise, consist 
essentially of, and/or consist of peptides having a length of at 
least about 4, 6, 8, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50,55, 60, 
65, 70, 75, 80, 85,90, 95, 100, 110, 125, 150, 175, 182,200, 
or more consecutive amino acids, including without limita 
tion any lengths within these ranges not explicitly recited 
herein of consecutive amino acids up to the full length of a 
polypeptide or amino acid sequence according to the inven 
tion. 
0043. The amino acid sequences of this invention are pre 
sented in the amino to carboxy direction, from left to right. 
Any nucleotide sequences are presented in the 5' to 3' direc 
tion, from left to right. Nucleic acids can be either single or 
double Stranded (i.e., including the complementary nucleic 
acid). A nucleic acid can be the complement (e.g., comple 
mentary to the full length or only to a portion) of a nucleic acid 
described. 
0044) The present invention further includes isolated 
polypeptides, peptides, proteins, fragments, domains and/or 
nucleic acid molecules that encode polypeptides and frag 
ments thereof that are substantially equivalent to those 
described for the embodiments of this invention. As used 
herein, "isolated polypeptide means a polypeptide that is 
separated or substantially free from at least some of the other 
components of the naturally occurring organism or virus, for 
example, the cell or viral structural components or other 
polypeptides or nucleic acids commonly found associated 
with the polypeptide. In particular embodiments, the “iso 
lated” polypeptide is at least about 1%. 5%, 10%, 25%, 50%, 
60%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 
more pure (w/w). In other embodiments, an "isolated 
polypeptide indicates that at least about a 5-fold, 10-fold, 
25-fold, 100-fold, 1000-fold, 10,000-fold, or more enrich 
ment of the protein (w/w) is achieved as compared with the 
starting material. 
0045. As used herein, “substantially equivalent can refer 
both to nucleic acid and amino acid sequences, for example a 
mutant sequence, that varies from a reference sequence by 
one or more Substitutions, deletions, or additions, the net 
effect of which does not result in an undesirable adverse 
functional dissimilarity between reference and subject 
sequences. In some embodiments, this invention can include 
Substantially equivalent sequences that have an adverse func 
tional dissimilarity. For purposes of the present invention, 
sequences having equivalent biological activity and equiva 
lent expression characteristics are considered Substantially 
equivalent. Moreover, “substantially equivalent can refer to 
the biological activity of polypeptide fragments, domains, 
portions, etc. having about 50%, 60%, 75%, 85%, 90%. 95%, 
97%, 98%, 99%, or more, of the biological activity of the 
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native polypeptide (and can even have a higher level of activ 
ity than the native polypeptide). 
0046. As used herein, “therapeutically effective amount 
refers to an amount of an agent, i.e., ephrin, or composition 
that is sufficient to produce the desired therapeutic effect. The 
therapeutically effective amount will vary with the age and 
physical condition of the subject, the severity of the disorder, 
the duration of the treatment, the nature of any concurrent 
treatment, the pharmaceutically acceptable carrier used, and 
like factors within the knowledge and expertise of those 
skilled in the art. An appropriate “therapeutically effective 
amount in any individual case can be determined by one of 
ordinary skill in the art by reference to the pertinent texts and 
literature and/or by using routine experimentation. (See, for 
example, Remington, The Science and Practice of Pharmacy 
20th Edition, Lippincott Williams & White, Baltimore, Md. 
(2000). 
0047. The therapeutically effective amount, the use of 
which is in the scope of present invention, will vary somewhat 
from Subject to Subject, and will depend upon factors such as 
the age and condition of the subject and the route of delivery. 
Such dosages can be determined in accordance with routine 
pharmacological procedures known to those skilled in the art. 
For example, an ephrin of the present invention can be admin 
istered to the Subject in an amount ranging from a lower limit 
of about 0.01, 0.02. 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, or 
0.1 mg to an upper limit of about 0.1, 0.2,0.3, 0.4,0.5,0.6, 
0.7, 0.8, 0.9, 1.0, 2.0, 3.0.4.0, 5.0, 6.0, 7.0, 8.0,9.0, or 10.0 mg 
in a single dose; in an amount ranging from a lower limit of 
about 0.01, 0.02. 0.03,0.04, 0.05, 0.06, 0.07, 0.08, 0.09, or 0.1 
mg to an upper limit of about 0.1, 0.2,0.3, 0.4,0.5,0.6, 0.7. 
0.8, 0.9, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 
12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0 or 20.0 mg in a 24 
hour period; and as much as 30, 40, 50, 60, 70, 80, 90, 100, 
200, 300, 400, 500 mg or more over a prolonged period of 
time with a medical infusion pump (external or implanted) or 
similar device designed for delivery of a substance over a 
prolonged period. The frequency of administration can be 
one, two, three, four, five times or more per day or as neces 
sary to control the condition. The duration of therapy depends 
on the type of condition being treated and can be for as long 
as the life of the subject. In humans, the United States Food 
and Drug Administration (FDA) defines the maximum rec 
ommended therapeutic dose (MRTD) as 0.00001 to 1000 
mg/kg body weight per day (Contrera 2004), and this dose 
would be dependent on the route of administration (i.e. sys 
temically vs. directly into the heart). 
0048. As used herein, a “pharmaceutically acceptable car 
rier according to the present invention is a component Such 
as a carrier, diluent, or excipient of a composition that is 
compatible with the other ingredients of the composition in 
that it can be combined with the agents and/or compositions 
of the present invention without eliminating the biological 
activity of the agents or the compositions, and is suitable for 
use in Subjects as provided herein without undue adverse side 
effects (such as toxicity, irritation, allergic response, and 
death). Side effects are “undue' when their risk outweighs the 
benefit provided by the pharmaceutical composition. Non 
limiting examples of pharmaceutically acceptable compo 
nents include, without limitation, any of the standard phar 
maceutical carriers such as phosphate buffered saline 
Solutions, water, sterile water, polyethylene glycol, polyvinyl 
pyrrolidone, lecithin, arachis oil, Sesame oil, emulsions such 
as oil/water emulsions or waterfoil emulsions, microemul 
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sions, and various types of wetting agents. Additives Such as 
water, alcohols, oils, glycols, preservatives, flavoring agents, 
coloring agents, Suspending agents, and the like may also be 
included in the composition along with the carrier, diluent, or 
excipient. 
0049 “Kitas used herein refers to an assembly of com 
ponents. The assembly of components can be a partial or 
complete assembly. Instructions for use of the kit or use of 
various components of the kit are optionally included. 
0050. As used herein, “administered at the time of means 
that the ephrin or composition including an ephrin according 
to embodiments of the present invention is administered at a 
time Sufficiently close to the onset of an impetus causing 
injury, a time sufficiently close to the onset of the actual injury 
or a time sufficiently close to the manifestation of physical 
symptoms characteristic of the injury. If administered at the 
time of injury, the ephrin or composition including an ephrin 
according to embodiments of the present invention may 
reduce injury or prevent further injury. 'Administered after 
means that the ephrin or composition including an ephrin 
according to embodiments of the present invention is admin 
istered after the onset of an impetus causing injury, after the 
onset of the actual injury or after the manifestation of physical 
symptoms characteristic of the injury. If administered after 
injury, the ephrin or composition including an ephrin accord 
ing to embodiments of the present invention may reduce 
injury or prevent further injury. Administered before” means 
that the ephrin or composition including an ephrin according 
to embodiments of the present invention is administered 
before the onset of an impetus causing injury, before the onset 
of the actual injury or before the manifestation of physical 
symptoms characteristic of the injury. If administered before, 
the ephrin or composition including an ephrin according to 
embodiments of the present invention may be used as a pre 
ventive treatment. 
0051. In view of the foregoing, embodiments according to 
the present invention relate to methods of reducing injury 
following cardiovascular disease in a subject in need thereof, 
comprising administering to the Subject a therapeutically 
effective amount of an ephrin. That is, injury in the presence 
ofatherapeutically effective amount of ephrin is less than that 
in the absence of ephrin or does not worsen substantially in 
the presence of ephrin thereby reducing the extent of injury 
that may occur following cardiovascular disease. In particular 
embodiments, cardiovascular disease comprises myocardial 
infarction. In still other embodiments, the cardiovascular dis 
ease comprises heart failure, peripheral arterial disease or 
stroke. 
0052 Embodiments of the present invention address 
injury that may occur to the cardiovascular system, including 
the heart, arteries, veins, arterioles, Venules, and capillaries. 
In some embodiments, the type of injury may include, but is 
not limited to, infarct size, necrosis, chamber dilation, wall 
thinning, inflammation, apoptotic cell death, autophagy, 
hypertrophy of remote myocardium, fibrosis, or a combina 
tion thereof. 
0053 According to embodiments of the present invention, 
the ephrin is administered at the time of the injury. In other 
embodiments, the ephrin is administered after the injury. In 
still other embodiments, the ephrin is administered before the 
injury. 
0054. In some embodiments of the present invention, the 
ephrin is administered to a subject believed to be at risk for 
injury to the cardiovascular system. In some embodiments, 
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the subject is believed to be at risk for myocardial infarction. 
Subjects at risk for injury to the cardiovascular system or at 
risk for myocardial infarction can be determined by use of 
clinical parameters and/or assessments known to those 
skilled in the art of diagnosing and/or treating the same, for 
example, physical examinations, detection of signs and 
symptoms of heart disease, or myocardial infarction specifi 
cally, electrocardiogram, echocardiogram, chest X-ray, blood 
tests to detect cardiac biomarkers, etc. 
0055 Embodiments of the present invention further 
include methods of promoting myocardial repair following 
cardiovascular disease in a Subject in need thereof, compris 
ing administering to the Subject a therapeutically effective 
amount of an ephrin. That is, injury to the myocardium may 
be repaired, e.g., reversed or maintained at the same or similar 
level in the presence of a therapeutically effective amount of 
ephrin compared to that observed in the absence of ephrin 
following cardiovascular disease. In particular embodiments, 
the cardiovascular disease is myocardial infarction. The eph 
rins suitable for use in such embodiments of the present 
invention have been described previously herein. 
0056. In some embodiments of the present invention, 
myocardial repair can be an improvement or a decrease in 
infarct size, necrosis, apoptosis, autophagy, angiogenesis, 
remodeling, chamber dilation, wall thinning, inflammation, 
reduction in serum cardiac troponin I and/or other markers of 
cardiomyocyte degradation or a combination thereof. 
0057. In further embodiments of the present invention, the 
ephrin is administered at the time of the onset of heart disease. 
In other embodiments, the ephrin is administered after the 
onset of heart disease. In still other embodiments, the ephrin 
is administered before the onset of heart disease. 
0.058 According to further embodiments of the present 
invention, ephrins can be administered as an adjunct to (or in 
combination with) reperfusion therapy. In particular, ephrin 
therapy can be administered (a) at the time of injury, (b) at the 
time of reperfusion, (c) during reperfusion and/or (d) at the 
time of injury and during reperfusion. The ephrin may be 
administered from 0, 1,2,3,4,5,6,7,8,9, 10, 12, 15, 30, 60, 
90, 120, 180, 240, 300 or 360 minutes before the time of 
reperfusion, or the ephrin may be administered at any period 
of time from the time of injury before and up to the time of 
reperfusion. The ephrin may further be administered every 1, 
2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 30 minutes or more during 
the first hour of reperfusion, or any number of times during 
the first hour of reperfusion. Alternatively, the ephrin may be 
administered via a slow release to provide a more constant 
dosage level of ephrin for a period of time Such as days or 
weeks before, at the time of and during reperfusion. 
0059 Embodiments of the present invention further pro 
vide pharmaceutical compositions that comprise, consist 
essentially of or consist of an ephrin and a pharmaceutically 
acceptable carrier. The ephrin can be any ephrinas described 
herein. In some embodiments, the pharmaceutical composi 
tion includes at least one agent useful for treating myocardial 
infarction and/or reducing myocardial injury. Agents that 
may be useful in a combination therapy with an ephrin, 
include, but are not limited to, thrombolytics, antiplatelet 
agents, anticoagulants, beta blockers, angiotensin-converting 
enzyme (ACE) inhibitors, 3-hydroxy-3-methylglutaryl 
(HMG)-CoA reductase inhibitors, glycosides, diuretics, 
aldosterone receptor modulators and further including agents 
such as statins, digoxin, SDF-1a, Thymosin B4, VEGF, IGF 
and those that promote progenitor cell homing to the site of 
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injury, enhance revascularization, and/or cell Survival. Eph 
rins can be administered in combination with stem cell 
therapy to promote Survival, adhesion, retention of trans 
planted cells. “In combination” means that the two agents, 
compounds and/or therapies are administered closely enough 
in time that the presence of one alters the biological effects of 
the other. The two may be administered simultaneously (i.e., 
concurrently) or sequentially. Simultaneous administration 
may be carried out by mixing prior to administration, or by 
administering at the same point in time but at different ana 
tomic sites or using different routes of administration. Fur 
ther, the phrases “concurrent administration.” “administra 
tion in combination,” “simultaneous administration' or 
“administered simultaneously” can be employed inter 
changeably. Moreover, the pharmaceutical compositions of 
the present invention may be used and/or administered in the 
same manner as described herein for the use and administra 
tion of the ephrin. 
0060 Embodiments of the present invention also provide 
kits comprising a composition comprising, consisting essen 
tially of or consisting of an ephrin in a pharmaceutically 
acceptable carrier and a container suitable for delivery of the 
composition by way of a parenteral delivery device. In some 
embodiments, the parenteral delivery device is an intramyo 
cardial administration device. Instruments of containment are 
those that can be used to deliver, place, attach, or insert the 
ephrin into the myocardium, for example, a intramyocardial 
device for intramyocardial delivery of the ephrin to the sub 
ject. Such containers include, but are not limited to, vials, 
ampoules, tubes, capsules, bottles, Syringes, and bags. 
0061 The ephrins described above can be formulated for 
administration in accordance with known pharmacy tech 
niques. See, e.g., Remington, The Science and Practice of 
Pharmacy 20th Edition, Lippincott Williams & White, Bal 
timore, Md. (2000). In the manufacture of a pharmaceutical 
composition according to the present invention, the active 
agent (including the physiologically acceptable salts thereof) 
is typically admixed with, interalia, an acceptable carrier. The 
carrier must, of course, be acceptable in the sense of being 
compatible with any other ingredients in the formulation and 
must not be deleterious to the patient. The carrier can be a 
solid or a liquid, or both, and is preferably formulated with the 
compound as a unit-dose formulation, for example, a tablet, 
which can contain from 0.01% or 0.5% to 95% or 99%, or any 
value between 0.01% and 99%, by weight of the active com 
pound. One or more active compounds can be incorporated in 
the compositions of the invention, which can be prepared by 
any of the well-known techniques of pharmacy, comprising 
admixing the components, optionally including one or more 
accessory ingredients. Moreover, the carrier can be preserva 
tive free. 
0062. The formulations of the present invention can 
include those Suitable for oral, rectal, topical, inhalation (e.g., 
via anaerosol) buccal (e.g., Sub-lingual), vaginal, topical (i.e., 
both skin and mucosal Surfaces, including airway Surfaces), 
transdermal administration and parenteral or infusion (e.g., 
Subcutaneous, intramuscular, intradermal, intraarticular, 
intrapleural, intraperitoneal, intrathecal, intracerebral, intrac 
ranially, intramyocardial, intraarterial or intravenous), 
although the most Suitable route in any given case will depend 
on the nature and severity of the condition being treated and 
on the nature of the particular active compound which is 
being used. 
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0063 Particular routes of parenteral administration 
include intravenous, intraarterial, intramyocardial injection, 
controlled, delayed release (implantable devices such as 
implanted infusion devices or pumps, for example, osmotic 
pumps, or using nanoparticles or other bioengineered mate 
rials and/or cells for Sustained release. 
0064. Formulations suitable for oral administration can be 
presented in discrete units, such as capsules, cachets, loZ 
enges, or tablets, each containing a predetermined amount of 
the active agent; as a powder or granules; as a solution or a 
Suspension in an aqueous or non-aqueous liquid; or as an 
oil-in-water or water-in-oil emulsion. Such formulations can 
be prepared by any suitable method of pharmacy which 
includes bringing into association the active agent and a Suit 
able carrier (which can contain one or more accessory ingre 
dients as noted above). In general, the formulations of the 
invention are prepared by uniformly and intimately admixing 
the active agent with a liquid or finely divided solid carrier, or 
both, and then, if necessary, shaping the resulting mixture. 
For example, a tablet can be prepared by compressing or 
molding a powder or granules containing the active agent, 
optionally with one or more accessory ingredients. Com 
pressed tablets can be prepared by compressing, in a Suitable 
machine, the agentina free-flowing form, Such as a powder or 
granules optionally mixed with a binder, lubricant, inert dilu 
ent, and/or Surface active/dispersing agent(s). Molded tablets 
can be made by molding, in a suitable machine, the powdered 
agent moistened with an inert liquid binder. 
0065 Formulations of the present invention suitable for 
parenteral administration comprise Sterile aqueous and non 
aqueous injection solutions of the active agent, which prepa 
rations are preferably isotonic with the blood of the intended 
recipient. These preparations can contain, buffers and solutes 
which render the formulation isotonic with the blood of the 
intended recipient. Aqueous and non-aqueous sterile Suspen 
Sions can include Suspending agents and thickening agents. 
The formulations can be presented in unit\dose or multi-dose 
containers, for example sealed ampoules and vials, and can be 
stored in a freeze-dried (lyophilized) condition requiring only 
the addition of the sterile liquid carrier, for example, saline or 
water-for-injection immediately prior to use. Extemporane 
ous injection solutions and Suspensions can be prepared from 
sterile powders, granules and tablets of the kind previously 
described. 
0.066 For example, in some embodiments of the present 
invention, there is provided an injectable, stable, Sterile com 
position comprising an active agent, or a salt thereof, in a unit 
dosage form in a sealed container. The agent or salt is pro 
vided in the form of a lyophilizate which is capable of being 
reconstituted with a suitable pharmaceutically acceptable 
carrier to form a liquid composition Suitable for injection 
thereof into a Subject. The unit dosage form typically com 
prises from about 10 mg to about 10 grams of the agent or salt. 
When the agent or salt is substantially water-insoluble, a 
Sufficient amount of emulsifying agent which is physiologi 
cally acceptable can be employed in Sufficient quantity to 
emulsify the agent or salt in an aqueous carrier. Non-limiting 
examples of agents that contribute to the pharmaceutical 
acceptability of the compositions of the present invention 
include normal saline, phosphatidylcholine, and glucose. In 
Some embodiments, the pharmaceutically acceptable carrier 
can be normal saline. In other embodiments, the pharmaceu 
tically acceptable carrier can be normal saline with up to 0.0, 
0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 1.0, 2.0, 
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3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10, 11, 12, 13, 14, 15, 16, 17, 
18, 19, and 20%, and any value between 0.01% and 20%, 
glucose. 
0067. Formulations suitable for transdermal administra 
tion can be presented as discrete patches adapted to remain in 
intimate contact with the epidermis of the recipient for a 
prolonged period of time. Formulations suitable for transder 
mal administration can also be delivered by iontophoresis 
(see, for example, Pharmaceutical Research 3(6):318 (1986)) 
and typically take the form of an optionally buffered aqueous 
Solution of the active agent. Suitable formulations comprise 
citrate or bis\tris buffer (pH 6) or ethanol/water and contain 
from 0.1 to 0.2M active ingredient. 
0068. Further, the present invention provides liposomal 
formulations of the agents disclosed herein and salts thereof. 
The technology for forming liposomal suspensions is well 
known in the art. When the agent or salt thereof is an aqueous 
soluble salt, using conventional liposome technology, the 
same can be incorporated into lipid vesicles. In Such an 
instance, due to the water Solubility of the agent or salt, the 
agent or salt will be substantially entrained within the hydro 
philic center or core of the liposomes. The lipid layer 
employed can be of any conventional composition and can 
either contain cholesterol or can be cholesterol-free. When 
the agent or salt of interest is water-insoluble, again employ 
ing conventional liposome formation technology, the salt can 
be substantially entrained within the hydrophobic lipid 
bilayer which forms the structure of the liposome. In either 
instance, the liposomes which are produced can be reduced in 
size, as through the use of Standard Sonication and homog 
enization techniques. 
0069. The liposomal formulations containing the agents 
disclosed herein or salts thereof, can be lyophilized to pro 
duce a lyophilizate which can be reconstituted with a phar 
maceutically acceptable carrier, Such as water, to regenerate a 
liposomal Suspension. 
0070. In addition to active agents or their salts, the phar 
maceutical compositions can contain other additives, such as 
pH-adjusting additives. In particular, useful pH-adjusting 
agents include acids, such as hydrochloric acid, bases or 
buffers, such as Sodium lactate, Sodium acetate, Sodium phos 
phate, Sodium citrate, sodium borate, or sodium gluconate. 
Further, the compositions can contain microbial preserva 
tives. Useful microbial preservatives include methylparaben, 
propylparaben, and benzyl alcohol. The microbial preserva 
tive is typically employed when the formulation is placed in a 
vial designed for multidose use. The pharmaceutical compo 
sitions of the present invention can be lyophilized using tech 
niques well known in the art. 
0071. In particular embodiments, the ephrin is adminis 
tered via intramyocardial injection. In this instance, the 
needle may be inserted into the left ventricle above and to the 
right of the site of coronary ligation. It is advanced toward the 
border Zone of infarcted to non-infarcted tissue, where the 
protein is then delivered and when the “bleb' that is formed 
dissipates, the needle may be slowly withdrawn. 
0072. In other embodiments, the ephrin is administered 
via single or repetitive intracoronary, intravenous, Subcuta 
neous, or intraperitoneal route, which may be performed any 
time during or after the injury or when the occlusion is 
removed and coronary flow is restored. 
0073 Subjects suitable to be treated according to the 
present invention include, but are not limited to, avian and 
mammalian Subjects, and are preferably mammalian. Mam 
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mals of the present invention include, but are not limited to, 
canines, felines, bovines, caprines, equines, Ovines, porcines, 
rodents (e.g. rats and mice), lagomorphs, primates, humans, 
and the like, and mammals in utero. Any mammalian Subject 
in need of being treated according to the present invention is 
suitable. Human subjects are preferred. Human subjects of 
both genders and at any stage of development (i.e., neonate, 
infant, juvenile, adolescent, adult) can be treated according to 
the present invention. 
0074 Illustrative avians according to the present invention 
include chickens, ducks, turkeys, geese, quail, pheasant, 
ratites (e.g., ostrich) and domesticated birds (e.g., parrots and 
canaries), and birds in ovo. 
0075. The present invention is primarily concerned with 
the treatment of human Subjects, but the invention can also be 
carried out on animal Subjects, particularly mammalian Sub 
jects Such as mice, rats, dogs, cats, livestock and horses for 
Veterinary purposes, and for drug screening and drug devel 
opment purposes. 
0076 Suitable subjects additionally include subjects who 
are at risk for cardiovascular disease or have cardiovascular 
disease, those who are at risk for myocardial infarction or 
have suffered a myocardial infarction and/or those who are at 
risk for myocardial injury or have experienced myocardial 
injury including those Suffering from or at risk for acute 
coronary events and those Suffering from more long-term 
coronary disease Such as congestive heart failure. 
(0077. The present invention will now be described with 
reference to the following examples. It should be appreciated 
that these examples are for the purposes of illustrating aspects 
of the present invention, and do not limit the scope of the 
invention as defined by the claims. 
Example 1 
Methods 
0078 All procedures were approved by the East Carolina 
University Institutional Animal Care and Use Committee and 
the investigation conforms to the Guide for the Care and Use 
of Laboratory Animals published by the US National Insti 
tutes of Health (NIH Publication No. 85-23, revised 1996). 
Animals 
(0079 Six week old B6/129S breeder pairs were obtained 
from Jackson Laboratories (Bar Harbor, Me.) to establish an 
in-house colony (strain #101045). Animals were housed in 
12-12 light/dark cycle conditions and received food and water 
ad libitum. 
Surgical Procedure 
0080 Male 8-10 week old mice (22-28 g) were anesthe 
tized (20 ul/g Avertin i.p.), intubated, and mechanically ven 
tilated. The left anterior descending (LAD) coronary artery 
was permanently ligated using 8-0 Suture. Sham controls in 
which the suture was pulled through the heart but not ligated, 
and either IgG-Fc or ephrinA1-Fc was injected, were done to 
ensure that there was no injury caused by the injection (data 
not shown). Infarction was confirmed by blanching of the 
myocardium distal to the site of ligation. Following coronary 
occlusion, using a Hamilton Syringe with a sterile 30 gauge 
needle, animals received a single intramyocardial injection of 
either 6 ug IgG-Fc (R&D #110-HG), or 6 ug ephrin Al-Fc 
(Sigma #E9902) resuspended in 6 ul sterile PBS at the peri 
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infarct Zone. This dose was chosen based on prior studies 
showing effective doses of intramyocardial injections of TB4 
(Bock-Marquette et al., 2004) and intraperitoneal injection of 
ephrinB2-Fc (Mansson-Broberg et al., 2008). Additionally, 
this dose is within the therapeutic range (for humans) of the 
maximum recommended therapeutic dose (MRTD) 0.00001 
to 1000 mg/kg-bw/day, as defined by the FDA (Contrera et 
al., 2004). Taking into account heart weight, potential for 
efflux of the protein from the heart via the injection site, and 
that an average mouse left ventricle weighs approximately 
150 mg, injecting 6 ug of protein intramyocardially is within 
this range (approximately 40 mg/kg). The investigator per 
forming the Surgery was blinded as to the treatment, which 
were randomized by another investigator. Once the animals 
recovered, they were returned to the Vivarium. The surgical 
procedure is described in more detail elsewhere (Virag & 
Murry, 2003: Viraget al., 2010). 
0081 Four days after surgery, mice were given a 0.5 ml i.p. 
injection of 5-bromodeoxyuridine 5 mg/ml) to label prolifer 
ating endothelial cells and anesthetized 1 hour later with an 
i.p. injection of 0.1 mL pentobarbital (390 mg/mL) (Virag & 
Murry, 2003). The heart was arrested in diastole using cold 
KCl (30 mM), excised, rinsed in PBS, and immersed in Zinc 
fixative with a segment of Small intestine (used as a positive 
control for BrdU proliferating cells). Hearts were sectioned 
transversely into 4 slices of equal thickness and were pro 
cessed and embedded in paraffin. Routine histological (hema 
toxylin and eosin) procedures and immunostaining were per 
formed using 5 um sections, as described below (Virag & 
Murry, 2003). 
EphrinA1-Fc Distribution in the Myocardium 
0082 To determine the distribution pattern and duration of 
persistence of ephrin Al-Fc in the nonreperfused myocar 
dium, an anti-human IgG-Fc was used to immunolocalize the 
ephrin A1 chimera in hearts at 30 min, 4 hr, and 24 h post 
injection (n=3 per group). A representative image (FIG. 1) 
shows prominent epicardial and transmural staining at 30 
min. Light staining was observed in 2 of 3 hearts at 4 hr but 
none was observed at 24 hr or 4 days post injection, Saline 
injected hearts, or in tissues incubated without the primary 
antibody (data not shown). 
Histology and Morphometry 
0083. Images of four haematoxylin and eosin-stained sec 
tions per heart were taken at 20x magnification using a DP70 
digital camera. Two sections of infarct, approximately 1 mm 
apart (apical and closer to the ligation site) and two sections of 
base in non-infarcted regions, also 1 mm apart, were used. 
Scion imaging Software (Scion Corporation, Frederick, Md., 
USA) was used to trace the cross sectional area of the left 
ventricular wall and chamber, as well as the infarct Zone 
(necrosis-granulation tissue) and necrosis. Measurements 
from three to four complete, transverse profiles perheart were 
averaged. Septal and free wall thicknesses were also mea 
Sured using the average of three radial measures in each of 
two sections containing infarct. The investigator was blinded 
as to the treatment while obtaining morphometric measure 
ments. After determining that there was no significant differ 
ence between IgG-Fc-treated hearts and standard 4 day-inf 
arcted hearts without any injection, we used 4 day MI hearts 
for protein and RNA analysis, and this experimental group is 
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labelled as MI rather than IgG-Fc, which was the group used 
for histological and immunohistochemical analysis. 
Immunostaining 
I0084 Tissue sections were deparaffinized in xylene and 
endogenous peroxidases quenched with 3% H0 in metha 
nol. Slides were rinsed in PBS and incubated with anti-eph 
rinA1 (Zymed #34-3300), CD45 (PharMingen, #550539; 
1:2000) for leukocytes, Ly6G (PharMingen #550291) for 
neutrophils, or CD31 (PharMingen #553371) and anti-BrdU 
(Roche #11585860001) for proliferating endothelial cells. 
Slides were incubated with appropriate biotinylated second 
ary antibodies and then with Avidin Biotin Complex (Vector 
Labs PK-6100). The reaction product was visualized with 
DAB (Vector, SK-4 100), counterstained with methyl green, 
dehydrated in Xylene, and slides were coverslipped. For the 
ephrin A1 staining, a second antibody, anti-ephrin A1 (Santa 
Cruz, fisc-911) was used to Verify consistent staining pattern. 
Negative controls were performed in the same manner but 
without a primary antibody. For mast cell staining, slides 
were sent to Histo-Scientific Research Laboratories (Mount 
Jackson, Va.) for pinacyanol erthrosinate staining to identify 
mast cells (Murray et al., 2004). Leukocyte, neutrophil, and 
mast cell density was measured in 3 fields per section of 2 
sections of infarcted heart at 400x. Results were expressed as 
the number of cells per 0.1 mm. Forproliferating endothelial 
cells (BrdU"+CD31), numbers are expressed as a percent 
age of 1000 endothelial cells (CD31* only). 
Cardiac Troponin I (cTnI) Measurements 
I0085. Approximately 50-100 ul of whole blood was col 
lected from mice pre-Surgery and at the time of euthanasia by 
a submandibular bleed, stored in lithium heparin coated tubes 
on a rocker to prevent clotting, and analyzed within 30 min 
utes of collection on an i-STAT Handheld Clinical Analyzer 
with cTnI cartridges (Abbott Labs). Values are expressed as 
nanograms per milliliter. 
Protein Isolation 
I0086 Whole left ventricles (LV) were snap frozen in liq 
uid nitrogen at the time of collection, and stored at -80° C. 
until use. The whole LV was homogenized in a lysis buffer 
containing 50 mM hepes, 10 mM EDTA, 100 mM NaF. 50 
mM Na pyrophosphate, and 1% each of protease and phos 
phatase inhibitors. Protein was quantified using the Bradford 
Assay. 
Western Blotting 
I0087 Western blotting was performed on a 4-12% gradi 
ent Bis-Tris gel (BioRad) in 1xMOPS running buffer. 50ug of 
sample was loaded per well, and the gel was run for 1 hour at 
155V, and transferred for 55 minutes (for ephrin A1, BAG-1 
and GAPDH) or 1 hr 30 min (for cleaved PARP, AKT, and 
pAKT) onto pure nitrocellulose membranes (BioRad). The 
membrane was incubated with one of the following antibod 
ies: cleaved PARP (89 kDa: Cell Signaling #9544; 1:1000), 
ephrin A1 (28 kDa; Santa Cruz, sc-911; 1:100), AKT (Cell 
Signaling #4691, 1:1000), phospho-AKT (Cell Signaling 
#4060, 1:2000), and GAPDH (37 kDa; Millipore #MAB374; 
1:100), followed by appropriate secondary antibodies. Eph 
rinA1 and cleaved PARP were run on the same membrane, 
which was cut horizontally at 50 kDa, with the bottom half of 
the membrane used for the ephrin A1 blot, and the top half 
used for the cleaved PARP blot. The ephrinA1 blot was then 
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stripped/reprobed for anti-GAPDH to confirm equal protein 
loading. All blots were detected with Amersham ECL 
Advance (GE Healthcare iRPN2135) and imaged on a 
Typhoon Imager. Densitometry was performed using Image J 
Software and the intensity of each protein was normalized to 
GAPDH. In the case of p AKT/AKT, the amount of phospho 
rylated AKT protein was normalized to total AKT. 
RNA Extraction and Real-Time RT-PCR 
0088. The Trizol method was used for RNA isolation, 
followed by the Quiagen RNeasy kit for additional purifica 
tion. cDNA was synthesized using a high capacity cDNA kit. 
Real-time RT-PCR was conducted on an Applied Biosystems 
thermocycler. A reaction mixture of 10 LIL containing 100 ng 
RNA was amplified using recommended conditions for Taq 
Man primers provided by Applied Biosciences. TaqMan 
primers and probes were obtained from Applied Biosciences 
(EphrinA1: Mm00438660 ml), EphA1: Mm004.45804 m1, 
EphA2: Mm00438726 m1, EphA3: Mm00580743 m1, 
EphA4: Mm00433056 m1, EphA5: Mm00433074 m1, 
EphA6: Mm00433094 m1, EphA7: Mm00833876 m1, 
GAPDH: Mm99999915 g1). In each experiment, fluores 
cence data were analyzed using the AACT method. Gene 
expression was normalized to the housekeeping gene 
GAPDH. No Template Controls (NTC) were included in each 
experiment, and all samples were run in triplicate. 
Statistics 
0089 Student t-tests were used to test statistical signifi 
cance between 4 day MI and ephrin Al-Fc-treated MI for 
RT-PCR, relative infarct size, and necrosis. ANOVAs and 
student Newman-Keuls post-hoc analyses were used to deter 
mine differences between control, 4 day MI, and ephrin Al 
Fc-treated MI for cTnI, inflammatory cell density, chamber 
area, and left ventricular free wall thickness. The number of 
hearts analyzed for each endpoint and significance levels 
have been specified for each experiment in reference to the 
figures. Four animals were excluded from all experiments: 
two from each group, based on Suboptimal cTnI and/or over 
all health of the animals. 
Example 2 
EphrinA1-Fc Reduces Infarct Size, Necrosis, 
Chamber Dilation, and Left Ventricular Free Wall 
Thinning 
0090 Ephrin Al-Fc or IgG-Fc was injected into the border 
Zone of the infarct immediately after coronary ligation. Four 
days after Surgery, tissue was collected and either fixed for 
histology and immunohistochemistry, or frozen for RNA and 
protein isolation, Overall survival for this study was 70%, and 
there was no difference in survival between experimental 
groups. Histological staining and morphometric analyses 
(FIG. 2) show a 50% reduction in the size of the infarct 
(expressed as a percent of the left ventricle), 64% less necrotic 
area, a 35% reduction in chamber dilation, and 32% less 
thinning of the infarcted left ventricular free wall. There was 
no significant difference in chamber area between uninjured 
control hearts and those treated with ephrin Al-FC at day 4 
post-MI. 
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Example 3 
Cardiac Troponin I Levels Reduced with 
ephrin Al-FC Administration 
0091 Serum cTnI levels were measured prior to surgery 
and at the time of euthanasia (four days post-MI) in the same 
animals. There was an 89% increase in cTnI levels following 
MI in vehicle treated hearts. However, cTnI levels in eph 
rinA1-Fc treated hearts were 54% lower than those from 
vehicle treated animals (FIG. 3A). There was no significant 
difference between pre-surgery levels and those of ephrinA1 
Fc treated animals four days post-Surgery. 
Example 4 
EphrinA1-Fc Treated Hearts Show Diminished 
cleaved PARP Expression and Increased BAG-1 
Expression 
0092 Cleaved PARP, the main target of caspase-3 and an 
indicator of increased apoptosis (Nicholson et al., 1995; Tew 
ari et al., 1995; Oliver et al., 1998), increased by approxi 
mately 88% in response to MI, but diminished with eph 
rin Al-Fc treatment (FIG.3B) below control levels. Although 
we did not observe a change in the level of Bcl-2 protein 
expression with ephrin Al-Fc treatment (data not shown), we 
did observe a change in Bcl-2-associated athanogene-1 
(BAG-1). BAG-1 is a protein that enhances the anti-apoptotic 
effects of Bcl-2 and has also been identified as a cardiopro 
tective protein through interactions with heat shock proteins 
(Doong et al., 2002; Townsend et al., 2004). EphrinA1-Fc 
administration upregulated the expression of the BAG-1 pro 
tein by approximately 54% (FIG. 3C). 
Example 5 
EphrinA1-Fc Treatment Reduces Inflammatory Cell 
Infiltration to Infarcted Myocardium 
0093. Results indicate a 57% reduction in neutrophilden 
sity (FIG. 4A) and a 21% reduction in leukocyte density in 
ephrin Al-Fe-treated versus IgG-Fc-treated hearts at 4 days 
post-MI (FIG. 4B), indicating ephrin Al-Fc attenuates the 
inflammatory response. No statistical differences were 
observed in the numbers of mast cells between ephrin Al-Fc 
and vehicle treated hearts, with only a few (1-6 persection of 
LV) mast cells per heart (data not shown). 
Example 6 
EphrinA1-Fc Treatment Does not Influence the 
Angiogenic Response to MI 
0094. No differences were seen in endothelial cell prolif 
eration (5.0+1% vs. 6.1+1.3%; n=3 vehicle, n=5 ephrinA1 
Fc) or capillary density (111+26.4 vs. 111+26.0 vessels per 
40x high power field, n=4 per group) between vehicle- and 
ephrin Al-Fe-treated hearts, respectively. 
Example 7 
Ephrin A1 and EphA Receptor Gene Expression in 
Response to Ephrin Al-Fc Treatment 
0.095 Ephrin A1 gene expression was quantified using 
qRT-PCR. mRNA levels decrease significantly by 35% fol 
lowing MI, and remain unchanged with ephrin Al-Fc treat 
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ment (FIG. 5). Of the eight receptors, EphA1, A2, A3, and A7 
were all significantly upregulated four days after MI (5-fold, 
2-fold, 5-fold, and 28%, respectively); Eph A1 and A2 were 
further upregulated with ephrinA1-Fc treatment (10-fold and 
3-fold, respectively, from control). Despite not changing in 
response to MI, EphA4 was significantly upregulated 2-fold 
with ephrin Al-Fc treatment. Eph A6 was detected in control 
hearts, but significantly decreased in response to MI, and 
expression in the ephrinA 1-Fc-treated group was unchanged 
relative to the untreated MI group (FIG. 5). Ligands eph 
rinA2-A5 and EphrinB3 (the only Bligand known to bind to 
an EphA receptor, specifically, EphA4) were also detected in 
the heart, but their expression did not change in response to 
MI or ephrinA1-Fc administration (data not shown). 
Example 8 
Endogenous Ephrin A1 Tissue Expression Pattern 
post-MI and in Response to EphrinA1-Fc Treatment 
0096. In uninjured control hearts, endogenous ephrin A1 
protein expression appeared to be expressed at a low, basal 
level on cardiac myocytes throughout the myocardium 
(FIGS. 6A and D). Four days after MI, ephrinA1 protein 
expression was expressed in cardiomyocytes throughout the 
uninjured regions of the hearts and was also localized to the 
spared cardiac myocytes on both the epicardial and endocar 
dial surfaces of the myocardium, at the border Zones of the 
infarct (FIGS. 6B and 6E). In the ephrinA1-Fc-treated hearts 
at 4 days post-MI, endogenous ephrinA1 protein expression 
appeared to be localized not only to the cardiomyocytes, but 
also to infiltrating granulation tissue cells throughout the 
infarct Zone (FIGS. 6C and F). 
Example 9 
Ephrin A1 Protein Expression Post-MI and in 
Response to EphrinA1-Fc Treatment 
0097 Western blotting was used to quantify endogenous 
ephrin A1 expression. Since anti-IgG-Fc immunostaining 
(FIG. 1) shows that expression of the chimeric protein is 
greatly reduced by 4 hours post-injection, and completely 
abolished by 24 hours, ephrinA1 protein expression detected 
at 4 days is only the endogenous protein. In addition, the 
molecular weight for the chimera is 42 kDa (not observed), 
vs. 28 kDa for the native protein. Endogenous ephrin A1 pro 
tein expression decreased 50% with MI, but was only dimin 
ished by approximately 36% with ephrinA 1-Fc treatment 
(FIG. 6G). 
Example 10 
EphrinA1-Fc Administration Increases p AKT/Total 
AKT Ratio 
0098 Total and phosphorylated AKT protein was mea 
sured using western blotting. While total AKT remained 
unchanged in the three groups (Control. 4 day MI, and Eph 
rin Al-Fc treated), phosphorylated AKT levels increased with 
EphrinA1-Fc treatment following MI (FIG. 7A). The paKT/ 
AKT ratio was significantly higher in the MI group compared 
to control, and further increased in ephrin Al-Fe-treated 
hearts compared to both control and ML 
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Example 11 
NF-kB p65 Protein Reduced with EphrinA1-fc 
Administration 
(0099 Protein levels of nuclear factor K light-chain 
enhancer of activated B cells (NF-kB) were measured with 
Western blotting, and a trend for reduced expression of this 
immune-modulatory protein with ephrin Al-Fc administra 
tion was observed (FIG. 7B). 
Example 12 
Comparison of Infarct Size in Reperfused Versus 
Nonreperfused Myocardium 
0100 Currently, reperfusion is the only treatment known 
to improve longevity in patients with acute myocardial inf 
arction. Reperfusion can accelerate phagocytic resorption of 
necrotic myocardium and expedite its replacement with 
granulation tissue, thus reducing remodeling. However, this 
therapy is generally applied within 6 hours following the 
occlusive event in order to Salvage any of the highly ischemia 
sensitive myocardial tissue. The therapeutic efficacy of rep 
erfusion generally declines exponentially within hours of 
occlusion onset, causes additional oxidative stress and, if flow 
is not restored, infarct injury proceeds and accelerates, with 
poor long-term prognosis. 
0101 This experiment is designed to compare the infarct 
size in reperfused versus nonreperfused myocardium follow 
ing 1) sham operation, 2) intramyocardial IgG-Fc adminis 
tration, 3) intramyocardial ephrin Al-Fc injection, and 4) an 
intravenous (i.v.) injection of ephrin Al-Fc. The following 
table illustrates the groups and number of mice needed for 
each (assuming at least 85% survival). 
Experiment #1: 
01.02 
Un- 6 Jug 2011g 
Experimental treated 6 g IgG-Fc ephrinA1-Fc ephrinA1 
Groups sham intramyocardial intramyocardial Fc i.v. 
4 day 4: 4: 4: 12 
nonreperfused 
30 min If4 day 12 12 12 12 
reperfusion 
*additions to existing data sets (Dries et al. (2011).J. Physiol. 589: 1725-1740) 
0103 Baseline serum troponin I (TnI) is measured prior to 
Surgery and again prior to sacrifice as an index of myocardial 
damage. Similarly, baseline cardiac function (fractional 
shortening, ejection fraction, LV mass, and systolic and dias 
tolic dimensions) of each animal prior to Surgery and again 
prior to sacrifice is performed using echocardiographic analy 
ses. In control animals and at the time of sacrifice of the 
experimental animals, in Vivo pressure-volume analysis (HR, 
ESBP. EDBP. ESV, EDV, SV, EF--/-dP/dt) is performed via 
catheterization using a 1.4 Fr conductance catheter. Animals 
are given an intraperitoneal injection of isoproterenol (0.25 
mg/kg) to assess their contractile reserve in response to acute 
cardiovascular stress. ECG recordings are obtained and 
arrhythmia scores are be generated. Histologic examination 
and morphometric analyses are be performed to measure 
US 2014/0056925 A1 
12 
differences in infarct size, composition (necrosis and granu 
lation tissue), and Ventricular dimensions (septal and free 
wall thickness). 
Example 13 
Presence of Ephrin Al-Fc in the Myocardium 
Relative to the Area at Risk During Intravenous 
Administration Compared to Intramyocardial 
Administration 
0104 Immunohistochemistry is used to evaluate the pres 
ence and distribution of ephrin A1-Fe in the heart relative to 
the area at risk (TTC staining) when administered intrave 
nously compared to intramyocardial injection. Ephrin Al-Fc 
is administered intramyocardially or with an i.v., injection at 
the time of ligation in mice and the table below describes the 
experimental groups and numbers of mice in each group. 
Experimental 6 Jug ephrinA1-Fc 20 g ephrinA1-Fc 
Groups intramyocardial i.v. 
2 hr nonreperfused 10 10 
30 min I2 hr reperfusion 10 10 
0105. The foregoing is illustrative of the present invention, 
and is not to be construed as limiting thereof. The invention is 
defined by the following claims, with equivalents of the 
claims to be included therein. 
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SEQUENCE LISTING 
<16 Os NUMBER OF SEO ID NOS: 4 
<21 Os SEQ ID NO 1 
&211s LENGTH: 2O5 
212s. TYPE: PRT 
<213> ORGANISM: Mus musculus 
<4 OOs SEQUENCE: 1 
Met Glu Phe Lieu. Trp Ala Pro Lieu. Lieu. Gly Lieu. Cys Cys 
1. 5 1O 
Ala Ala Asp Arg His Ile Val Phe Trp Asn. Ser Ser Asn 
2O 25 
Arg Glu Glu Asp Tyr Thr Val His Val Glin Lieu. ASn Asp 
35 4 O 45 
Ile Ile Cys Pro His Tyr Glu Asp Asp Ser Val Ala Asp 
SO 55 60 
Glu Arg Tyr Thr Lieu. Tyr Met Val Glu. His Glin Glu Tyr 
65 70 7s 
Gln Pro Glin Ser Lys Asp Glin Val Arg Trp Asn. Cys Asn 
85 90 
Ala Lys His Gly Pro Glu Lys Lieu. Ser Glu, Llys Phe Glin 
1OO 105 
Pro Phe Ile Leu Gly Lys Glu Phe Lys Glu Gly His Ser 
115 12O 125 
Ile Ser Lys Pro Ile Tyr His Glin Glu Ser Glin Cys Lieu 
13 O 135 14 O 
Val Thr Val Asn Gly Lys Ile Thr His Asn Pro Glin Ala 
145 15 O 155 
Pro Glin Glu Lys Arg Lieu. Glin Ala Asp Asp Pro Glu Val 
1.65 17 O 
His Ser Ile Gly Tyr Ser Ala Ala Pro Arg Lieu Phe Pro 
18O 185 
Ala Wall Lieu. Lieu. Lieu Pro Lieu Lleu Lleu Lieu. Glin Ser Glin 
195 2 OO 2O5 
<21 Os SEQ ID NO 2 
&211s LENGTH: 142 
212s. TYPE: PRT 
<213> ORGANISM: Mus musculus 
<4 OOs SEQUENCE: 2 
Met Glu Arg Tyr Thr Lieu. Tyr Met Val Glu. His Glin Glu 
1. 5 1O 
(0197) Wykosky J & Debinski W. (2008). The EphA2 
receptor and ephrin A1 ligand in Solid tumors: function and 
therapeutic targeting. Mol Cancer Res 6, 1795-1806. 
(0198 Wykosky J. Gibo D M, Stanton C & Debinski W. 
(2005). EphA2 as a novel molecular marker and target in 
glioblastoma multiforme. Mol Cancer Res 3, 541-551, 
(0199. Wykosky J, Palma E, Gibo DM, Ringler S, Turner C 
P& Debinski W. (2008). Soluble monomeric EphrinA1 is 
released from tumor cells and is a functional ligand for the 
Eph A2 receptor. Oncogene 27, 7260-7273. 
(0200 Zhou R. (1998). The Eph family receptors and 
ligands. Pharmacol Ther 77, 151-181. 
Ser Lieu. Ala 
15 
Pro Llys Phe 
3 O 
Tyr Lieu. Asp 
Ala Ala Met 
Wall Ala Cys 
Arg Pro Ser 
95 
Arg Phe Thr 
110 
Llys Lieu Lys 
His Wall Asn 
16 O 
Glin Wall Lieu. 
17s 
Lieu Val Trp 
190 
Tyr Val Ala 
15 
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Cys Glin Pro Glin Ser Lys Asp Glin Val Arg Trp Asn. Cys Asn Arg Pro 
2O 25 3O 
Ser Ala Lys His Gly Pro Glu Lys Lieu. Ser Glu, Llys Phe Glin Arg Phe 
35 4 O 45 
Thr Pro Phe Ile Lieu. Gly Lys Glu Phe Lys Glu Gly His Ser Tyr Tyr 
SO 55 6 O 
Tyr Ile Ser Llys Pro Ile Tyr His Glin Glu Ser Glin Cys Lieu Lys Lieu. 
65 70 7s 8O 
Llys Val Thr Val Asn Gly Lys Ile Thr His Asn Pro Glin Ala His Val 
85 90 95 
Asn Pro Glin Glu Lys Arg Lieu. Glin Ala Asp Asp Pro Glu Val Glin Val 
1OO 105 11 O 
Lieu. His Ser Ile Gly Tyr Ser Ala Ala Pro Arg Lieu. Phe Pro Lieu Val 
115 12 O 125 
Trp Ala Val Lieu Lleu Lleu Pro Lieu. Lieu. Lieu. Lieu. Glin Ser Glin 
13 O 135 14 O 
<210s, SEQ ID NO 3 
&211s LENGTH: 2O5 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 3 
Met Glu Phe Lieu. Trp Ala Pro Lieu. Lieu. Gly Lieu. Cys Cys Ser Lieu. Ala 
1. 5 1O 15 
Ala Ala Asp Arg His Thr Val Phe Trp Asn. Ser Ser Asn. Pro Llys Phe 
2O 25 3O 
Arg Asn. Glu Asp Tyr Thir Ile His Val Glin Lieu. Asn Asp Tyr Val Asp 
35 4 O 45 
Ile Ile Cys Pro His Tyr Glu Asp His Ser Val Ala Asp Ala Ala Met 
SO 55 6 O 
Glu Glin Tyr Ile Leu Tyr Lieu Val Glu. His Glu Glu Tyr Glin Lieu. Cys 
65 70 7s 8O 
Glin Pro Glin Ser Lys Asp Glin Val Arg Trp Glin Cys Asn Arg Pro Ser 
85 90 95 
Ala Lys His Gly Pro Glu Lys Lieu. Ser Glu Lys Phe Glin Arg Phe Thr 
1OO 105 11 O 
Pro Phe Thr Lieu. Gly Lys Glu Phe Lys Glu Gly His Ser Tyr Tyr Tyr 
115 12 O 125 
Ile Ser Llys Pro Ile His Gln His Glu Asp Arg Cys Lieu. Arg Lieu Lys 
13 O 135 14 O 
Val Thr Val Ser Gly Lys Ile Thr His Ser Pro Glin Ala His Asp Asn 
145 150 155 160 
Pro Glin Glu Lys Arg Lieu Ala Ala Asp Asp Pro Glu Val Arg Val Lieu. 
1.65 17O 17s 
His Ser Ile Gly His Ser Ala Ala Pro Arg Lieu. Phe Pro Lieu Ala Trp 
18O 185 19 O 
Thir Wall Lieu Lleu Lleu Pro Lieu. Lieu. Lieu. Lieu. Glin Thr Pro 
195 2OO 2O5 
<210s, SEQ ID NO 4 
&211s LENGTH: 183 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
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<4 OOs, SEQUENCE: 4 
Met Glu Phe Lieu. 
1. 
Trp Ala Pro Lieu. Lieu. Gly Lieu. 




Thir Ile His Wall Glin Lieu. ASn 
4 O 








Cys Pro His Asp His Ser Asp 
Glu 
65 
Glin Ile Wall Glu Glu Tyr Lieu. Tyr Lieu. His Glu 
70 
Gln Pro Glin Ser Lys Glin Wall Glin Asn 
85 
Asp Arg Trp 
90 
Ala Glu Ser Glu Phe Glin 
105 







Pro Lieu. Gly Gly His 











Wall Wall His Ser Ile 
155 
Asp Asp Pro Arg Luell 
Ala Ala Lieu. Phe Pro Lieu. Ala Thir Wall Leu 
1.65 
Pro Arg Trp 
17O 
Leul Glin. Thir Pro 
18O 
Lieu. Luell Luell 
What is claimed is: 
1. A pharmaceutical composition comprising: 
an ephrin; and 
a pharmaceutically acceptable carrier. 
2. The pharmaceutical composition of claim 1, wherein the 
pharmaceutical composition is a parenteral composition. 
3. The pharmaceutical composition of claim 2, wherein the 
parenteral composition is selected from the group consisting 
of a Subcutaneous, intramuscular, intradermal, intraarticular, 
intrapleural, intraperitoneal, intrathecal, intracerebral, intrac 
ranially, intramyocardial, intraarterial and intravenous com 
position. 
4. The pharmaceutical composition of claim3, wherein the 
parenteral composition is an intravenous composition. 
5. The pharmaceutical composition of claim3, wherein the 
parenteral composition is an intramyocardial composition. 
6. The pharmaceutical composition of claim3, wherein the 
parenteral composition is a Subcutaneous composition. 
7. The pharmaceutical composition of claim 1, wherein the 
pharmaceutical composition is a controlled ordelayed release 
composition. 
8. The pharmaceutical composition of claim 7, wherein the 
controlled or delayed release composition is an implantable 
composition. 
9. The pharmaceutical composition of claim 7, wherein the 






























10. The pharmaceutical composition of claim 1, wherein 
the ephrin is an ephrin-A class ephrin. 
11. The pharmaceutical composition of claim 1, wherein 
the ephrin is ephrin A1, ephrin A2, ephrin A3, ephrin A4. 
ephrin A5, or a combination thereof. 
12. The pharmaceutical composition of claim 1, wherein 
the ephrin is ephrin A1. 
13. The pharmaceutical composition of claim 1, wherein 
the ephrin comprises ephrin Al-Fc. 
14. The pharmaceutical composition of claim 1 further 
comprising an agent useful for treating myocardial infarction. 
15. Akit comprising a composition comprising an ephrin in 
a pharmaceutically acceptable carrier and a container Suitable 
for delivery of the composition into a parenteral administra 
tion device optionally comprising instructions for use of the 
components of the kit. 
16. The kit of claim 15, wherein the parenteral administra 
tion device is an intramyocardial administration device. 
17. The kit of claim 15, wherein the ephrin is an ephrin-A 
class ephrin. 
18. The kit of claim 15, wherein the ephrin is ephrin A1, 
ephrin A2, ephrin A3, ephrin A4, ephrin A5, or a combination 
thereof. 
19. The kit of claim 15, wherein the ephrin is ephrin A1. 
20. The kit of claim 15, wherein the ephrin comprises 
ephrin Al-FC. 
